Table 3.
Univariable Logistic regression for objective response rate to first exposure CPI
| Variable | Univariable | |
| OR (95% CI) | P value | |
| First CPI exposure | ||
| Anti-PD-1 | 1 | |
| Anti-PD-1/ipilimumab | 2.14 (1.16 to 3.97) | 0.0004 |
| Ipilimumab | 0.49 (0.24 to 0.97) | 0.0016 |
| Primary acral melanoma site | ||
| Subungual | 1 | |
| Plantar | 1.51 (0.77 to 2.97) | 0.62 |
| Palmar | 3.12 (1.08 to 8.95) | 0.05 |
| Sex | ||
| Female | 1 | |
| Male | 0.63 (0.38 to 1.04) | 0.07 |
| Ethnicity | ||
| Non-Caucasian | 1 | |
| Caucasian | 1.30 (0.67 to 2.50) | 0.44 |
| Stage of advanced disease | ||
| Unresectable IIIB | 1 | |
| Unresectable IIIC | 3.41 (0.38 to 30.24) | 0.03 |
| Unresectable IIID | 2.67 (0.24 to 30.07) | 0.40 |
| M1a | 1.65 (0.17 to 14.81) | 0.92 |
| M1b | 1.80 (0.20 to 16.15) | 0.82 |
| M1c | 2.45 (0.29 to 21.97) | 0.15 |
| M1d | 0.55 (0.04 to 7.09) | 0.09 |
| LDH | ||
| Normal (≤ULN) | 1 | |
| Elevated (>ULN) | 1.03 (0.53 to 2.00) | 0.93 |
| ECOG | ||
| 0 | 1 | |
| ≥1 | 0.68 (0.39 to 1.21) | 0.19 |
CPI, immune checkpoint inhibitor; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PD-1, programmed cell death protein-1; ULN, upper limited of normal.